## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.0% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($221.31)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook**
- Source: ts2.tech | 20260102T193252 | Somewhat-Bullish | Relevance: 100%
- AbbVie shares saw a slight increase after its partner Ironwood Pharmaceuticals raised its 2026 outlook for the constipation drug Linzess and announced a list price reduction. Ironwood expects 2026 U.S. net sales for Linzess to be between $1.125 billion and $1.175 billion, up from 2025 guidance. This adjustment aims to support patient access and reflects ongoing scrutiny of drug pricing in the pharmaceutical industry.

**2. AbbVie stock ends 2025 lower as markets shut for New Year — what ABBV investors watch next**
- Source: ts2.tech | 20260101T205811 | Somewhat-Bearish | Relevance: 100%
- AbbVie stock closed 2025 down by 0.5% at $228.49 on Wednesday, as U.S. markets shut for the New Year's Day holiday. Investors are now looking ahead to the Federal Reserve's late-January meeting and AbbVie's mid-January dividend record date, with attention on whether the stock can hold above its 50-day moving average and reach its 52-week high in the post-Humira transition period. The drugmaker is focusing on newer immunology medicines like Skyrizi and Rinvoq to offset the decline of Humira.

**3. Shum Financial Group Inc. Takes $1.24 Million Position in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20260101T114703 | Bullish | Relevance: 100%
- Shum Financial Group Inc. has acquired a new stake of 5,336 shares in AbbVie Inc. (NYSE:ABBV) valued at approximately $1.24 million during the third quarter. This move is part of broader institutional adjustments, with analysts generally maintaining a "Moderate Buy" rating for AbbVie, setting a consensus target price of $245.84. Furthermore, AbbVie has increased its quarterly dividend to $1.73, offering an annualized dividend of $6.92 and a yield of approximately 3.0%.

**4. The Truth About AbbVie Inc (ABBV): Quiet Pharma Giant, Loud Money Moves**
- Source: AD HOC NEWS | 20260101T072347 | Bullish | Relevance: 100%
- AbbVie Inc (ABBV) is presented as a quiet pharmaceutical giant known for consistent dividends, strong cash flow, and significant R&D investments, positioning it as a steady compounder rather than a high-volatility stock. The article discusses its appeal to long-term investors seeking income and stability, while also noting risks like patent cliffs and regulatory scrutiny. It compares ABBV to competitors like Johnson & Johnson, highlighting AbbVie's focus on pharma and a stronger dividend growth narrative.

**5. The Truth About AbbVie Inc: Is ABBV the Sleeper Stock Gen Z Is Sleeping On?**
- Source: AD HOC NEWS | 20251231T140713 | Somewhat-Bullish | Relevance: 100%
- AbbVie Inc. (ABBV) is presented as a "sleeper stock" that Gen Z investors might be overlooking, despite its strong dividend yield and defensive characteristics. While not a viral stock like meme shares or AI companies, ABBV offers consistent income and portfolio stability, making it attractive for long-term investors focused on dividend growth rather than quick gains, weighing its established immunology pipeline against the “Humira hangover”.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $269 | $261 | +3% |
| 2025-12-10 | HSBC | $265 | $225 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Overweight |
| 2025-12-10 | HSBC | up | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.41 indicates undervaluation relative to growth. Forward P/E 16.1x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $405.3B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.41 |
| Forward P/E | 16.1 |
| Current P/E | 21.5 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_10 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 2.0pp (needs >3.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 54. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.03% (CS: 57) | Neutral |
| RSI_14 | 53.9 | Neutral |
| MACD Histogram | 0.41 | Bullish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.012x | Above |
| vs SMA200 | 1.112x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $229.31
- **Stop Loss:** $221.31 (3.5% risk)
- **Target:** $237.31 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 180
- **Position Value:** $41,275.80
- **Portfolio %:** 41.28%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*